Clinical and RNA expression integrated signature for urothelial bladder cancer prognosis

doi:10.3233/CBM-170314

	Clinical and RNA expression integrated signature for urothelial bladder cancer prognosis
	Xiong, Jie 1; Xiong, Ke 2; Bing, Zhitong3
刊名	CANCER BIOMARKERS
	2018
卷号	21 页码:535-546
关键词	Urothelial bladder cancer clinical RNA signature prognosis
ISSN号	1574-0153
DOI	10.3233/CBM-170314
英文摘要	BACKGROUND: Accumulating evidence shows that clinical factors alone are not adequate for predicting the survival of patients with urothelial bladder cancer (UBC), and many genes have been found to be associated with UBC prognosis. PURPOSE: The objective of this study is to develop a signature which integrates clinical and molecular information to predict the overall survival of UBC patients more accurate. MATERIALS AND METHODS: We integrated messenger RNA (mRNA) and microRNA (miRNA) expression profiles and the corresponding clinical data of 402 UBC patients and 19 normal controls from The Cancer Genome Atlas. Univariate Cox regression followed by a multiple testing correction and an elastic net-regulated Cox regression were adopted to identify a prognostic signature. RESULTS: We generated an integrated clinical-RNA signature which consisting of 3 clinical variables, 3 protective mRNAs, 7 risky mRNAs, 2 protective miRNAs and 1 risky miRNA. The area under the receiver operating characteristic curve of the integrated clinical-RNA signature was 0.802, larger than that of the clinical-alone signature (0.709) or the RNA-alone signature (0.726). UBC patients in the high-risk group had a significantly shorter overall survival time compared with patients in the low-risk group (clinical-RNA signature, hazard ratio = 2.441). CONCLUSIONS: Our conclusions that we have identified an integrated clinical-RNA signature that was superior to the traditional clinical-alone signature for ascertaining the overall survival prognosis of patients with UBC. These findings provide some novel genes for tumor molecular biologist to further study their functions and mechanisms in UBC tumorigenesis and malignance, and may be useful for effective clinical risk management of UBC patients.
资助项目	Postdoctoral Science Foundation of Central South University
WOS关键词	REGULARIZATION PATHS ; MICRORNA EXPRESSION ; COORDINATE DESCENT ; DOWN-REGULATION ; STAGE-TA ; CARCINOMA ; PROGRESSION ; RECURRENCE ; SURVIVAL ; CELLS
WOS研究方向	Oncology
语种	英语
出版者	IOS PRESS
WOS记录号	WOS:000426790200006
资助机构	Postdoctoral Science Foundation of Central South University
内容类型	期刊论文
源URL	[http://119.78.100.186/handle/113462/46364]
专题	中国科学院近代物理研究所
作者单位	1.Cent S Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China 2.Tongji Univ, Sch Med, Shanghai, Peoples R China 3.Chinese Acad Sci, Inst Modern Phys, Dept Computat Phys, Lanzhou, Gansu, Peoples R China
推荐引用方式 GB/T 7714	Xiong, Jie,Xiong, Ke,Bing, Zhitong. Clinical and RNA expression integrated signature for urothelial bladder cancer prognosis[J]. CANCER BIOMARKERS,2018,21:535-546.
APA	Xiong, Jie,Xiong, Ke,&Bing, Zhitong.(2018).Clinical and RNA expression integrated signature for urothelial bladder cancer prognosis.CANCER BIOMARKERS,21,535-546.
MLA	Xiong, Jie,et al."Clinical and RNA expression integrated signature for urothelial bladder cancer prognosis".CANCER BIOMARKERS 21(2018):535-546.